Prescient Therapeutics Limited PTX.AX Stock
Prescient Therapeutics Limited Price Chart
Prescient Therapeutics Limited PTX.AX Financial and Trading Overview
| Prescient Therapeutics Limited stock price | 0.06 AUD |
| Previous Close | 0.09 AUD |
| Open | 0.09 AUD |
| Bid | 0.08 AUD x 0 |
| Ask | 0.09 AUD x 0 |
| Day's Range | 0.08 - 0.09 AUD |
| 52 Week Range | 0.08 - 0.23 AUD |
| Volume | 327.91K AUD |
| Avg. Volume | 682.51K AUD |
| Market Cap | 66.82M AUD |
| Beta (5Y Monthly) | 0.926819 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.01 AUD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PTX.AX Valuation Measures
| Enterprise Value | 40.29M AUD |
| Trailing P/E | N/A |
| Forward P/E | 8.3 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 29.032482 |
| Price/Book (mrq) | 2.4411762 |
| Enterprise Value/Revenue | 17.505 |
| Enterprise Value/EBITDA | -7.223 |
Trading Information
Prescient Therapeutics Limited Stock Price History
| Beta (5Y Monthly) | 0.926819 |
| 52-Week Change | -49.41% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.23 AUD |
| 52 Week Low | 0.08 AUD |
| 50-Day Moving Average | 0.09 AUD |
| 200-Day Moving Average | 0.13 AUD |
PTX.AX Share Statistics
| Avg. Volume (3 month) | 682.51K AUD |
| Avg. Daily Volume (10-Days) | 580.07K AUD |
| Shares Outstanding | 805.02M |
| Float | 634.19M |
| Short Ratio | N/A |
| % Held by Insiders | 13.37% |
| % Held by Institutions | 0.068% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | -233.80% |
| Operating Margin (ttm) | -242.45% |
| Gross Margin | 100.00% |
| EBITDA Margin | -242.37% |
Management Effectiveness
| Return on Assets (ttm) | -15.51% |
| Return on Equity (ttm) | -24.78% |
Income Statement
| Revenue (ttm) | 2.3M AUD |
| Revenue Per Share (ttm) | 0.003 AUD |
| Quarterly Revenue Growth (yoy) | 48.89% |
| Gross Profit (ttm) | 1.89M AUD |
| EBITDA | -5578070 AUD |
| Net Income Avi to Common (ttm) | -5381011 AUD |
| Diluted EPS (ttm) | -0.01 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 20.97M AUD |
| Total Cash Per Share (mrq) | 0.03 AUD |
| Total Debt (mrq) | 0 AUD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 21.841 |
| Book Value Per Share (mrq) | 0.034 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -4827078 AUD |
| Levered Free Cash Flow (ttm) | -2860305 AUD |
Profile of Prescient Therapeutics Limited
| Country | Australia |
| State | VIC |
| City | Melbourne |
| Address | 100 Albert Road |
| ZIP | 3205 |
| Phone | 61 3 9692 7222 |
| Website | https://ptxtherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Q&A For Prescient Therapeutics Limited Stock
What is a current PTX.AX stock price?
Prescient Therapeutics Limited PTX.AX stock price today per share is 0.06 AUD.
How to purchase Prescient Therapeutics Limited stock?
You can buy PTX.AX shares on the ASX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Prescient Therapeutics Limited?
The stock symbol or ticker of Prescient Therapeutics Limited is PTX.AX.
Which industry does the Prescient Therapeutics Limited company belong to?
The Prescient Therapeutics Limited industry is Biotechnology.
How many shares does Prescient Therapeutics Limited have in circulation?
The max supply of Prescient Therapeutics Limited shares is 805.32M.
What is Prescient Therapeutics Limited Price to Earnings Ratio (PE Ratio)?
Prescient Therapeutics Limited PE Ratio is now.
What was Prescient Therapeutics Limited earnings per share over the trailing 12 months (TTM)?
Prescient Therapeutics Limited EPS is -0.01 AUD over the trailing 12 months.
Which sector does the Prescient Therapeutics Limited company belong to?
The Prescient Therapeutics Limited sector is Healthcare.